Development and evaluation of sustain release matrix tablet of metformin by using different polymer and comparison with marketed formulation

Section: Articles Published Date: 2024-11-12 Pages: 01-12 Views: 192 Downloads: 69

Authors

  • SHASHI KALA MEENA RKDF School of Pharmaceutical science, Bhabha University, Bhopal, (Madhya Pradesh)
  • SATKAR PRASAD RKDF School of Pharmaceutical science, Bhabha University, Bhopal, (Madhya Pradesh)
  • REENA YADAV RKDF School of Pharmaceutical science, Bhabha University, Bhopal, (Madhya Pradesh)
Download PDF
volume 7 issue 11

Abstract

This study was to develop and evaluate the sustain release matrix tablet of metformin by using different polymers and comparison with marked formulation. Sustained release dosage forms are designed to achieve a prolonged therapeutic effect by continuously releasing medication over an extended period of time after administration of a single dose. Sustained release dosage forms are prepared by coating the tablets so that the rate of solubility is controlled or individually encapsulating microparticles of varying sizes so that the rate of dissolution can be controlled. The release rate of Metformin from tablets was determined using USP Dissolution Testing Apparatus II and the data was analyzed using the zero-order graph of F3  formulation showing the constant drug release from the formulation. The Higuchi model is used to describe the limits for transport and drug release. Matrix tablets of Metformin were prepared by direct compression technique using varying proportions of polymers in combination with HPMC K-100, Eudragit RLPO, and other excipients like MCC, PVP, Talc, and Mg stearate. All the prepared tablets were evaluated for the test like hardness, friability, weight variation, disintegration time, drug content, and dissolution studies. Sustained-release tablets of Metformin have been successfully formulated using HPMC and Eudragit RLPO as drug-release modifiers.

Keywords

Metformin, Eudragit RLPO, Sustain release, HPMC